Xencor, Inc. (XNCR) - What Are Researchers Saying About This Stock?

Key Points

• Analyst sentiment is moderately bullish: Eleven firms rate Xencor “Moderate Buy,” with six buys, one strong buy, three holds and one sell. The average 12-month price target is $34, above the reported share price of $24.94.
• Xencor exceeded quarterly expectations: The biopharmaceutical company reported a loss of $0.29 per share versus the expected $0.80 loss, while revenue of $51.22 million surpassed estimates of $18.89 million and increased 17.4% year over year.
• Institutional interest has grown: BlackRock and Primecap Management initiated sizable positions during the second quarter, valued at approximately $219.8 million and $163.9 million, respectively, while other major investors also added or established stakes.

Shares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $34.00.

XNCR has been the topic of several analyst reports. Wedbush lifted their price target on shares of Xencor from $26.00 to $30.00 and gave the stock an "outperform" rating in a research note on Thursday, August 6th. JPMorgan Chase & Co. upped their price objective on Xencor from $14.00 to $21.00 and gave the stock a "neutral" rating in a research note on Thursday, September 3rd. Cantor Fitzgerald raised their target price on Xencor from $43.00 to $44.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Bank of America lifted their target price on Xencor from $20.00 to $26.00 and gave the company a "neutral" rating in a research report on Monday, September 21st. Finally, Raymond James Financial lifted their target price on Xencor from $40.00 to $46.00 and gave the company a "strong-buy" rating in a research report on Tuesday, September 1st.

Xencor Trading Up 7.5%

Shares of NASDAQ XNCR opened at $24.94 on Wednesday. The firm has a 50 day moving average of $25.24 and a 200 day moving average of $18.16. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of -11.49 and a beta of 0.89. Xencor has a 12-month low of $10.38 and a 12-month high of $30.61.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.80) by $0.51. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The business had revenue of $51.22 million during the quarter, compared to analysts' expectations of $18.89 million. During the same period in the prior year, the company earned ($0.41) earnings per share. The firm's revenue was up 17.4% on a year-over-year basis. Sell-side analysts predict that Xencor will post -3.05 EPS for the current year.

Institutional Trading of Xencor

Several institutional investors have recently made changes to their positions in XNCR. BlackRock Inc. purchased a new position in shares of Xencor in the second quarter worth $219,785,000. Primecap Management Co. CA bought a new position in shares of Xencor during the second quarter worth $163,919,000. Dimensional Fund Advisors LP grew its stake in Xencor by 3.6% during the first quarter. Dimensional Fund Advisors LP now owns 1,294,887 shares of the biopharmaceutical company's stock valued at $15,613,000 after acquiring an additional 45,599 shares in the last quarter. Legal & General Group Plc purchased a new position in Xencor during the second quarter valued at $17,568,000. Finally, Johnson & Johnson purchased a new position in Xencor during the second quarter valued at $12,043,798.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company headquartered in Monrovia, California. Founded in 1997, the company develops engineered antibodies and other biologic medicines for the treatment of cancer, autoimmune disorders and other serious diseases.

Xencor's research is centered on its XmAb technology platform, which is designed to modify antibodies to improve their therapeutic properties or create new antibody-based mechanisms. The platform supports the development of bispecific antibodies, immune-cell engagers and antibodies with extended activity in the body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.